[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608484":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":61,"collaborators":25,"id":63,"slug":25,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical treatment with Ultrasound","EXPERIMENTAL","10%TXA+2%Reduced Glutathione applied via ultrasound at 5W\u002Fcm² for 10mins",[13],"Device: 10%TXA+2%Reduced Glutathione applied via ultrasound at 5W\u002Fcm² in10min",{"label":15,"type":6,"description":16,"interventionNames":17},"Topical treatment without Ultrasound","10%TXA+2%Reduced Glutathione applied via ultrasound at 0W\u002Fcm² for 10mins",[18],"Other: 10%TXA+2%Reduced Glutathione applied via ultrasound at 0W\u002Fcm² 10min",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","10%TXA+2%Reduced Glutathione applied via ultrasound at 5W\u002Fcm² in10min","5w\u002Fcm² Ultrasound-assisted topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"10%TXA+2%Reduced Glutathione applied via ultrasound at 0W\u002Fcm² 10min","topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins",[15],[31],{"name":32,"affiliation":5,"role":33},"Lu Yan","STUDY_CHAIR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Lu Yan, phD","CONTACT","13913967126","luyan6289@163.com",{"name":36,"role":37,"phone":25,"phoneExt":41,"email":25},"Overall Study",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"The first Affiliated hospital with Nanjing medical university","RECRUITING","Nanjing","Jiangsu","210009","China",{"type":51,"coordinates":52},"Point",[53,54],118.77778,32.06167,{"lat":54,"lon":53},[57],{"name":58,"role":37,"phone":59,"phoneExt":25,"email":60},"Pan Yueyun","15851837753","15851837753@126.com",{"type":62,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100608484",false,"NCT07202156","Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma","Clinical Trial on the Efficacy and Safety of Ultrasound-Enhanced Delivery of Compound Tranexamic Acid Solution in the Treatment of Melasma","Inclusion Criteria:\n\n-(1) Male or female participants aged 20 to 55 years (inclusive); (2) Subjects clinically diagnosed with melasma and confirmed by the investigator to meet the trial requirements; (3) Subjects willing to comply with follow-up observations and able to provide portrait rights for documentation purposes; (4) Understanding and willingness to participate in the clinical trial, and voluntarily signing a written informed consent form.\n\nExclusion Criteria:\n\n* (1) Females who are pregnant, lactating, or planning to become pregnant during the trial period; (2) Subjects with known allergen to tranexamic acid or any excipient in the investigational product; (3) History of thrombosis or other thrombotic tendencies (e.g., hypertension, hyperlipidemia), or inability to discontinue oral contraceptives, estrogen, or prothrombin complex concentrates during the trial; (4) History of visual or ocular abnormalities (e.g. impaired vision, visual field defects, or fundus hemorrhage\u002Fedema) caused by abnormal retinal intravascular coagulation; (5) Patients with skin inflammation who have used topical steroid preparations for more than one month; (6) Presence of skin abnormalities at the trial site, such as nevi, ulcers, or erosions; (7) Any acute or chronic medical history (past or present) that may interfere with the validity or safety assessment of the trial; (8) Clinically significant abnormal laboratory test results prior to the trial; (9) Participation in any other clinical trial within 30 days prior to screening; (10) Any other condition deemed by the investigator to be unsuitable for participation in the study.","ALL","20 Years","55 Years",{"count":73,"type":74},35,"ESTIMATED","INTERVENTIONAL",[77],"NA","Melasma is a localized, acquired hyperpigmentary skin disorder characterized by well-defined, light to dark brown patches. Based on clinical practice and extensive literature reports, tranexamic acid and reduced Glutathione (GSH) are both applied in the treatment of melasma, but their water-soluble nature presents challenges for transdermal absorption. Our preliminary basic and clinical research has demonstrated that ultrasound-assisted delivery significantly enhances the absorption of tranexamic acid and other water-soluble components. Its effect on the skin barrier is temporary and reversible.\n\nThis study aims to evaluate the efficacy and safety of a compound solution (10% tranexamic acid, 2% GSH) delivered via ultrasound for melasma treatment through a split-face controlled trial.",[80],"Melasma (Facial Melasma)","2025-11-24",{"date":83,"type":84},"2025-11-25","ACTUAL",{"date":86,"type":84},"2024-10-20",{"date":88,"type":74},"2026-02-25",{"name":5,"class":6},1]